Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The endothelial lectin clearance receptor CLEC4M binds and internalizes Factor VIII in a VWF-dependent and -independent manner.

Swystun LL, Notley C, Georgescu I, Lai JD, Nesbitt K, James PD, Lillicrap D.

J Thromb Haemost. 2019 Feb 11. doi: 10.1111/jth.14404. [Epub ahead of print]

PMID:
30740857
2.

Genetic regulation of plasma von Willebrand factor levels in health and disease.

Swystun LL, Lillicrap D.

J Thromb Haemost. 2018 Dec;16(12):2375-2390. doi: 10.1111/jth.14304. Epub 2018 Oct 30. Review.

PMID:
30246494
3.

The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.

Swystun LL, Lai JD, Notley C, Georgescu I, Paine AS, Mewburn J, Nesbitt K, Schledzewski K, Géraud C, Kzhyshkowska J, Goerdt S, Hopman W, Montgomery RR, James PD, Lillicrap D.

J Clin Invest. 2018 Aug 31;128(9):4057-4073. doi: 10.1172/JCI96400. Epub 2018 Aug 20.

4.

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.

Lai JD, Swystun LL, Cartier D, Nesbitt K, Zhang C, Hough C, Dennis JW, Lillicrap D.

Haematologica. 2018 Nov;103(11):1925-1936. doi: 10.3324/haematol.2018.188219. Epub 2018 Jul 12.

5.

The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC, Lillicrap D, Hampshire DJ; European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups.

Blood Adv. 2018 Jul 10;2(13):1585-1594. doi: 10.1182/bloodadvances.2017011643.

6.

Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.

Lai JD, Cartier D, Hartholt RB, Swystun LL, van Velzen AS, den Haan JMM, Hough C, Voorberg J, Lillicrap D.

J Thromb Haemost. 2018 Mar;16(3):533-545. doi: 10.1111/jth.13936. Epub 2018 Feb 2.

PMID:
29285874
7.

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation.

Michels A, Swystun LL, Mewburn J, Albánez S, Lillicrap D.

J Vis Exp. 2017 Aug 14;(126). doi: 10.3791/55917.

PMID:
28829426
8.

Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.

Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D.

J Thromb Haemost. 2017 Aug;15(8):1607-1619. doi: 10.1111/jth.13749. Epub 2017 Jul 17.

PMID:
28581694
9.

Genetic diagnosis in hemophilia and von Willebrand disease.

Swystun LL, James PD.

Blood Rev. 2017 Jan;31(1):47-56. doi: 10.1016/j.blre.2016.08.003. Epub 2016 Aug 17. Review.

PMID:
27596108
10.

Histones link inflammation and thrombosis through the induction of Weibel-Palade body exocytosis.

Michels A, Albánez S, Mewburn J, Nesbitt K, Gould TJ, Liaw PC, James PD, Swystun LL, Lillicrap D.

J Thromb Haemost. 2016 Nov;14(11):2274-2286. doi: 10.1111/jth.13493.

11.

How much do we really know about von Willebrand disease?

Swystun LL, Lillicrap D.

Curr Opin Hematol. 2016 Sep;23(5):471-8. doi: 10.1097/MOH.0000000000000272. Review.

PMID:
27428891
12.

Extracellular Histones Increase Tissue Factor Activity and Enhance Thrombin Generation by Human Blood Monocytes.

Gould TJ, Lysov Z, Swystun LL, Dwivedi DJ, Zarychanski R, Fox-Robichaud AE, Liaw PC; Canadian Critical Care Translational Biology Group.

Shock. 2016 Dec;46(6):655-662.

PMID:
27405066
13.

The role of leukocytes in thrombosis.

Swystun LL, Liaw PC.

Blood. 2016 Aug 11;128(6):753-62. doi: 10.1182/blood-2016-05-718114. Epub 2016 Jun 27. Review.

14.

Gene Therapy for Coagulation Disorders.

Swystun LL, Lillicrap D.

Circ Res. 2016 Apr 29;118(9):1443-52. doi: 10.1161/CIRCRESAHA.115.307015. Review.

PMID:
27126652
15.

Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.

Wu C, Kim PY, Swystun LL, Liaw PC, Weitz JI.

J Thromb Haemost. 2016 Feb;14(2):366-74. doi: 10.1111/jth.13222. Epub 2016 Feb 1.

16.

Using genetic diagnostics in hemophilia and von Willebrand disease.

Swystun LL, James P.

Hematology Am Soc Hematol Educ Program. 2015;2015:152-9. doi: 10.1182/asheducation-2015.1.152. Review.

PMID:
26637715
17.

FVIII stabilization: VWF D'D3 will do.

Swystun LL, Lillicrap D.

Blood. 2014 Jul 17;124(3):313-5. doi: 10.1182/blood-2014-06-578955.

18.

Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms.

Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1977-84. doi: 10.1161/ATVBAHA.114.304114. Epub 2014 Jul 10.

PMID:
25012129
19.

Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption.

Lysov Z, Swystun LL, Kuruvilla S, Arnold A, Liaw PC.

Blood Coagul Fibrinolysis. 2015 Jan;26(1):36-45. doi: 10.1097/MBC.0000000000000145.

PMID:
24911456
20.

The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Rydz N, Swystun LL, Notley C, Paterson AD, Riches JJ, Sponagle K, Boonyawat B, Montgomery RR, James PD, Lillicrap D.

Blood. 2013 Jun 27;121(26):5228-37. doi: 10.1182/blood-2012-10-457507. Epub 2013 Mar 25.

21.

Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.

Elit LM, Lee AY, Parpia S, Swystun LL, Liaw PC, Hoskins P, Julian DH, Julian JA, Levine MN.

Thromb Res. 2012 Dec;130(6):894-900. doi: 10.1016/j.thromres.2012.09.010. Epub 2012 Oct 7.

PMID:
23046525
22.

Prognostic utility and characterization of cell-free DNA in patients with severe sepsis.

Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw KL, Weitz JI, Cook DJ, Fox-Robichaud AE, Liaw PC; Canadian Critical Care Translational Biology Group.

Crit Care. 2012 Aug 13;16(4):R151. doi: 10.1186/cc11466.

23.

Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus.

Swystun LL, Mukherjee S, Liaw PC.

J Thromb Haemost. 2011 Nov;9(11):2313-21. doi: 10.1111/j.1538-7836.2011.04465.x.

24.

Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.

Mukherjee SD, Swystun LL, Mackman N, Wang JG, Pond G, Levine MN, Liaw PC.

Pathophysiol Haemost Thromb. 2010;37(2-4):88-97. doi: 10.1159/000324166. Epub 2011 Mar 23.

PMID:
21430357
25.

The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models.

Swystun LL, Mukherjee S, Levine M, Liaw PC.

J Thromb Haemost. 2011 Apr;9(4):767-75. doi: 10.1111/j.1538-7836.2011.04232.x.

26.

Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes.

Swystun LL, Shin LY, Beaudin S, Liaw PC.

J Thromb Haemost. 2009 Apr;7(4):619-26. doi: 10.1111/j.1538-7836.2009.03300.x. Epub 2009 Jan 24.

27.

Protective effects of activated protein C in sepsis.

Toltl LJ, Swystun LL, Pepler L, Liaw PC.

Thromb Haemost. 2008 Oct;100(4):582-92. Review.

PMID:
18841279

Supplemental Content

Loading ...
Support Center